Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance
The share of stand-alone prescription drug plans using coinsurance for preferred brand name drugs surged in recent years, exposing more patients to list prices that are often artificially inflated.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
News
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Featured Experts: Erin Trish
In The News View All
Reuters
Padula provides insight on how rare disease therapies are influencing new drug pricing trends
Featured Experts: William Padula
STAT
Expanded coverage of GLP-1s is “probably the single most effective policy” for improving public health, Goldman says
Featured Experts: Dana Goldman
The Wall Street Journal
Many firms producing knockoff weight-loss drugs are “pushing the envelope” on legal requirements for compounders, Schiller says
Featured Experts: Lowell Schiller
Healthcare Dive
Sood recommends key PBM reforms in testimony before U.S. Senate panel
Featured Experts: Neeraj Sood
CalMatters
California’s proposal to establish fiduciary duty for PBMs would be an important cost-saving reform, Joyce says
Featured Experts: Geoffrey Joyce
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
